ArriVent BioPharma (NASDAQ:AVBP) Receives Outperform Rating from Oppenheimer

ArriVent BioPharma (NASDAQ:AVBP)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Oppenheimer in a research report issued on Friday,Benzinga reports. They currently have a $50.00 target price on the stock, up from their prior target price of $44.00. Oppenheimer’s target price would indicate a potential upside of 105.17% from the company’s previous close.

Several other research firms also recently weighed in on AVBP. Zacks Research upgraded ArriVent BioPharma from a “strong sell” rating to a “hold” rating in a research report on Friday, December 5th. Citigroup upped their price objective on shares of ArriVent BioPharma from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Friday. HC Wainwright raised their target price on shares of ArriVent BioPharma from $42.00 to $44.00 and gave the stock a “buy” rating in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of ArriVent BioPharma in a report on Wednesday, January 21st. Finally, Cantor Fitzgerald began coverage on shares of ArriVent BioPharma in a research note on Monday, December 22nd. They set an “overweight” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.11.

ArriVent BioPharma Price Performance

AVBP stock traded down $0.88 during midday trading on Friday, hitting $24.37. The stock had a trading volume of 781,627 shares, compared to its average volume of 467,482. The company’s 50-day moving average price is $22.17 and its 200 day moving average price is $20.89. The firm has a market cap of $1.01 billion, a PE ratio of -5.75 and a beta of 0.99. ArriVent BioPharma has a 12-month low of $15.47 and a 12-month high of $27.22.

ArriVent BioPharma (NASDAQ:AVBP) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.09. As a group, sell-side analysts anticipate that ArriVent BioPharma will post -2.74 EPS for the current year.

Institutional Investors Weigh In On ArriVent BioPharma

Several institutional investors have recently bought and sold shares of the business. Bessemer Group Inc. acquired a new stake in shares of ArriVent BioPharma during the third quarter valued at about $26,000. Russell Investments Group Ltd. lifted its stake in shares of ArriVent BioPharma by 9,747.6% in the third quarter. Russell Investments Group Ltd. now owns 2,068 shares of the company’s stock worth $38,000 after acquiring an additional 2,047 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in ArriVent BioPharma by 27.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,006 shares of the company’s stock valued at $40,000 after purchasing an additional 438 shares during the last quarter. BNP Paribas Financial Markets grew its stake in ArriVent BioPharma by 31.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,571 shares of the company’s stock valued at $56,000 after purchasing an additional 609 shares in the last quarter. Finally, Group One Trading LLC acquired a new stake in ArriVent BioPharma during the 4th quarter valued at approximately $57,000. 9.48% of the stock is currently owned by hedge funds and other institutional investors.

ArriVent BioPharma News Summary

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: Unusually large call buying: Traders bought ~1,832 call options on Friday (≈321% above typical call volume). Heavy call activity can indicate speculative bullish bets or hedging by sophisticated traders, which may drive short‑term upside interest in the shares.
• Positive Sentiment: HC Wainwright raised its price target from $42 to $44 and maintained a “buy” rating — implying ~83% upside from the cited $24.05 reference price. Analyst optimism and a higher target can attract momentum and institutional interest. Benzinga
• Positive Sentiment: Quarterly EPS beat: AVBP reported (‑$0.78) EPS vs. consensus (‑$0.87), beating by $0.09. An earnings beat for a clinical‑stage biotech reduces short‑term execution risk and can support valuation re‑rating. Earnings Release
• Positive Sentiment: Broker consensus: Coverage summary lists a “Moderate Buy” consensus from brokerages, which reinforces the positive analyst narrative and can support longer‑term inflows. Brokerage Consensus
• Neutral Sentiment: Full‑year 2025 financial results and company update were published (press release). The release provides corporate outlook and financials that investors will parse for cash runway, R&D progress and guidance — important but not an immediate directional catalyst until details are digested. Full Year 2025 Results
• Neutral Sentiment: Short‑interest data reported as zero shares with NaN changes — likely a data anomaly or reporting quirk. This makes short‑interest an unreliable driver currently; absence of meaningful short positions would remove a potential squeeze dynamic.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.